NIRVF (Nirvana Life Sciences) Tax Expense: $0.00 Mil (TTM As of Jan. 2026)


What is Nirvana Life Sciences Tax Expense?

Nirvana Life Sciences NIRVF Tax Expense is $0.00 Mil as of Jan. 2026. The stock has 3 warning signs investors should review.

Nirvana Life Sciences's tax expense for the months ended in Jan. 2026 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00 Mil.


Nirvana Life Sciences  (OTCPK:NIRVF) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Nirvana Life Sciences Tax Expense Related Terms


Nirvana Life Sciences Tax Expense Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences Tax Expense Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
Tax Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.00 Mil mean?
Nirvana Life Sciences (NIRVF) has a Tax Expense of $0.00 Mil as of Jan. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Nirvana Life Sciences and its competitors.
Is Nirvana Life Sciences' Tax Expense too high?
Nirvana Life Sciences' current Tax Expense is $0.00 Mil.
How does Nirvana Life Sciences' Tax Expense compare to VRTX and REGN?
Nirvana Life Sciences' Tax Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Nirvana Life Sciences and its competitors. Nirvana Life Sciences's current Tax Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current Tax Expense of $0.00 Mil. The current Tax Expense is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current Tax Expense is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.